Fish-Skin Medical...

Kerecis to use US$2 million investment to further develop its tissue-regeneration technology Reykjavik / Isafjordur, Iceland, February 21, 2014 – Kerecis Limited, the emerging tissue-regeneration...

Kerecis Receives...

Patent protects fish-skin invention across multiple medical areas Reykjavik / Isafjordur, February 13th, 2014 – Kerecis Limited, the emerging leader in tissue-regeneration materials, has been...

Does Fish Skin...

University Hospital of Iceland and Kerecis to collaborate on medical research Reykjavik / Isafjordur, January 24, 2014 – Kerecis Limited, the emerging leader in tissue-regeneration materials, and...

FDA Clears...

New treatment option for the millions suffering from chronic wounds Reykjavik / Isafjordur, November 7, 2013 – Kerecis Limited announced today that a 510(k) clearance has been received from the...

Kerecis Establishes...

Reykjavik / Isafjordur, Iceland, August 8, 2013 – Kerecis Limited, the emerging tissue-regeneration company, today announced the formation of a corporate scientific advisory board consisting of...

New Board Members...

Reykjavik / Isafjordur, Iceland, June 17, 2013 – Kerecis Limited, the emerging tissue-regeneration company, today announced that Andri Sveinsson and Kristjan Johannesson have been appointed to the...

Kerecis Completes...

Symposium on Advanced Wound Care, Denver, Colorado, May 3, 2013— Kerecis today announced that its recent clinical trial found no allergenic reactions to its fish-skin-composed MariGen Omega3...

Kerecis Completes...

Reykjavik / Isafjordur, Iceland, April 26, 2013 – Kerecis Limited, the emerging tissue-regeneration company, today announced that it has secured US$ 1 million in series A2 funding. The financing, a...

Kerecis Announces a...

Dubai, United Arab Emirates, January 31, 2013 — At the Arab Health Conference today, Kerecis announced the signing of a distribution agreement with Medline Industries, Inc. based in Mundelein,...

Follow-Up Study...

Reykjavik/Isafjordur, Iceland, May 18, 2012 — Kerecis, the emerging tissue-regeneration company, has successfully completed a 37-patient follow-up study of its MariGen Wound treatment product for...